Hepcidin Levels in Myelodysplastic Syndromes
Author Information
Author(s): Santini Valeria, Girelli Domenico, Sanna Alessandro, Martinelli Nicola, Duca Lorena, Campostrini Natascia, Cortelezzi Agostino, Corbella Michela, Bosi Alberto, Reda Gianluigi, Olivieri Oliviero, Cappellini Maria Domenica
Primary Institution: Hematology Unit, AOU Careggi, University of Florence, Florence, Italy
Hypothesis
Iron overload may represent an additional clinical problem in patients with Myelodysplastic Syndromes (MDS), with hepcidin dysregulation playing a role.
Conclusion
Hepcidin levels vary significantly across different MDS subtypes, which may influence treatment strategies.
Supporting Evidence
- Hepcidin levels were lowest in refractory anemia with ringed sideroblasts and highest in refractory anemia with excess blasts.
- MDS subtypes were significant predictors of hepcidin levels even after adjusting for ferritin and transfusion history.
- The hepcidin/ferritin ratio was significantly lower in the MDS population compared to controls.
Takeaway
This study looked at how a hormone called hepcidin, which controls iron in the body, behaves in patients with a blood disorder called MDS. They found that different types of MDS have different levels of hepcidin.
Methodology
Serum hepcidin was measured using a validated Mass-Spectrometry based method in 113 MDS patients and compared with 54 healthy controls.
Potential Biases
Potential biases may arise from the exclusion of patients treated with iron chelating agents.
Limitations
The study relies on ferritin levels as a marker of iron stores, which may not be entirely accurate.
Participant Demographics
Mean age of participants was 72.8 years, with 68.1% being male.
Statistical Information
P-Value
0.003
Confidence Interval
95% CI for hepcidin levels in MDS patients: 3.98–7.08 nM
Statistical Significance
p=0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website